vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Legacy Housing Corp (LEGH). Click either name above to swap in a different company.
Legacy Housing Corp is the larger business by last-quarter revenue ($25.5M vs $16.1M, roughly 1.6× Journey Medical Corp). Legacy Housing Corp runs the higher net margin — 32.2% vs -7.8%, a 39.9% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -30.6%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -9.1%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Legacy Housing Corp is a prominent U.S.-based manufacturer of affordable manufactured homes, tiny homes, and accessory dwelling units. It mainly caters to low- and middle-income consumers across North America, providing customizable residential solutions, supporting construction materials, and after-sales services for individual and community development clients.
DERM vs LEGH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $25.5M |
| Net Profit | $-1.2M | $8.2M |
| Gross Margin | — | 26.4% |
| Operating Margin | -2.8% | 40.4% |
| Net Margin | -7.8% | 32.2% |
| Revenue YoY | 27.3% | -30.6% |
| Net Profit YoY | -182.0% | -43.5% |
| EPS (diluted) | $-0.04 | $0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $25.5M | ||
| Q3 25 | $17.0M | $28.8M | ||
| Q2 25 | $15.0M | $38.4M | ||
| Q1 25 | $13.1M | $24.3M | ||
| Q4 24 | $12.6M | $36.7M | ||
| Q3 24 | $14.6M | $30.2M | ||
| Q2 24 | $14.9M | $31.7M | ||
| Q1 24 | $13.0M | $30.8M |
| Q4 25 | $-1.2M | $8.2M | ||
| Q3 25 | $-2.3M | $8.6M | ||
| Q2 25 | $-3.8M | $14.7M | ||
| Q1 25 | $-4.1M | $10.3M | ||
| Q4 24 | $1.5M | $14.5M | ||
| Q3 24 | $-2.4M | $15.8M | ||
| Q2 24 | $-3.4M | $16.2M | ||
| Q1 24 | $-10.4M | $15.1M |
| Q4 25 | — | 26.4% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 32.4% | ||
| Q1 25 | — | 29.2% | ||
| Q4 24 | 82.3% | 27.3% | ||
| Q3 24 | 63.9% | 29.2% | ||
| Q2 24 | 56.0% | 31.9% | ||
| Q1 24 | 47.7% | 33.6% |
| Q4 25 | -2.8% | 40.4% | ||
| Q3 25 | -9.0% | 33.7% | ||
| Q2 25 | -19.2% | 43.8% | ||
| Q1 25 | -25.3% | 47.7% | ||
| Q4 24 | 17.7% | 42.3% | ||
| Q3 24 | -19.8% | 50.8% | ||
| Q2 24 | -19.7% | 50.6% | ||
| Q1 24 | -77.4% | 54.3% |
| Q4 25 | -7.8% | 32.2% | ||
| Q3 25 | -13.6% | 30.0% | ||
| Q2 25 | -25.3% | 38.3% | ||
| Q1 25 | -31.0% | 42.3% | ||
| Q4 24 | 12.1% | 39.5% | ||
| Q3 24 | -16.3% | 52.4% | ||
| Q2 24 | -22.6% | 51.1% | ||
| Q1 24 | -80.1% | 49.1% |
| Q4 25 | $-0.04 | $0.38 | ||
| Q3 25 | $-0.09 | $0.35 | ||
| Q2 25 | $-0.16 | $0.60 | ||
| Q1 25 | $-0.18 | $0.41 | ||
| Q4 24 | $0.10 | $0.59 | ||
| Q3 24 | $-0.12 | $0.64 | ||
| Q2 24 | $-0.17 | $0.65 | ||
| Q1 24 | $-0.53 | $0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $8.5M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $528.6M |
| Total Assets | $94.6M | $580.3M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $8.5M | ||
| Q3 25 | $24.9M | $13.6M | ||
| Q2 25 | $20.3M | $2.6M | ||
| Q1 25 | $21.1M | $3.4M | ||
| Q4 24 | $20.3M | $1.1M | ||
| Q3 24 | $22.5M | $570.0K | ||
| Q2 24 | $23.9M | $60.0K | ||
| Q1 24 | $24.1M | $621.0K |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $528.6M | ||
| Q3 25 | $25.9M | $521.6M | ||
| Q2 25 | $19.2M | $512.8M | ||
| Q1 25 | $21.5M | $503.7M | ||
| Q4 24 | $20.1M | $494.0M | ||
| Q3 24 | $10.9M | $479.3M | ||
| Q2 24 | $11.3M | $463.2M | ||
| Q1 24 | $13.0M | $450.4M |
| Q4 25 | $94.6M | $580.3M | ||
| Q3 25 | $85.2M | $557.9M | ||
| Q2 25 | $81.2M | $552.0M | ||
| Q1 25 | $85.0M | $544.6M | ||
| Q4 24 | $80.2M | $534.2M | ||
| Q3 24 | $64.0M | $521.4M | ||
| Q2 24 | $65.2M | $514.9M | ||
| Q1 24 | $66.6M | $510.0M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $19.0M |
| Free Cash FlowOCF − Capex | — | $15.7M |
| FCF MarginFCF / Revenue | — | 61.6% |
| Capex IntensityCapex / Revenue | — | 13.1% |
| Cash ConversionOCF / Net Profit | — | 2.32× |
| TTM Free Cash FlowTrailing 4 quarters | — | $28.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $19.0M | ||
| Q3 25 | $-2.4M | $7.2M | ||
| Q2 25 | $-942.0K | $6.1M | ||
| Q1 25 | $-2.8M | $4.9M | ||
| Q4 24 | $2.2M | $7.9M | ||
| Q3 24 | $-1.2M | $13.8M | ||
| Q2 24 | $-5.2M | $3.5M | ||
| Q1 24 | $-5.0M | $10.8M |
| Q4 25 | — | $15.7M | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $3.7M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $6.0M | ||
| Q3 24 | — | $9.1M | ||
| Q2 24 | — | $1.7M | ||
| Q1 24 | — | $9.9M |
| Q4 25 | — | 61.6% | ||
| Q3 25 | — | 17.8% | ||
| Q2 25 | — | 9.6% | ||
| Q1 25 | — | 15.0% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | — | 30.2% | ||
| Q2 24 | — | 5.4% | ||
| Q1 24 | — | 32.2% |
| Q4 25 | — | 13.1% | ||
| Q3 25 | — | 7.1% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | 5.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 15.6% | ||
| Q2 24 | — | 5.5% | ||
| Q1 24 | — | 2.8% |
| Q4 25 | — | 2.32× | ||
| Q3 25 | — | 0.83× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | 1.46× | 0.54× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
LEGH
| Commercial Sales | $8.6M | 34% |
| Retail Store Sales | $6.0M | 24% |
| Inventory Finance Sales | $5.0M | 20% |
| Direct Sales | $4.4M | 17% |
| Other | $1.5M | 6% |
